Tag: Indacaterol

Cardiovascular disease is a significant comorbidity in approximately 38% of patients with Chronic Obstructive Pulmonary Disease (COPD). As a result, the question, 'Is indacaterol cardiac safety a concern?', is critically important for both patients and clinicians when considering long-term treatment for respiratory conditions.

The active ingredient in Onbrez is indacaterol maleate, which has been marketed under different brand names across the globe. Therefore, if you're asking what is the other name for Onbrez, the answer depends on the region, with its most notable alternative being Arcapta Neohaler in the United States.

In clinical trials, a post-inhalation cough was observed in 17-20% of patients using Onbrez Breezhaler, occurring within 15 seconds of inhalation [1.2.3, 1.2.5]. This article details what are the side effects of Onbrez Breezhaler, from common occurrences to serious adverse reactions.

Indacaterol, a once-daily inhaled bronchodilator, was the first ultra-long-acting beta2-agonist (LABA) approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is specifically prescribed for the long-term control of airflow blockage in patients with chronic bronchitis and emphysema.

The active ingredient in Onbrez, indacaterol, is an ultra-long-acting bronchodilator with a fast onset of action, working within five minutes of inhalation to provide relief for 24 hours. An **Onbrez inhaler** is a prescription dry powder device used for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD).